ar-c67085mx and Cardiovascular-Diseases

Endogenous nucleotides have widespread actions in the cardiovascular system, but it is only recently that the P2X and P2Y receptor subtypes, at which they act, have been identified and subtype-selective agonists and antagonists developed. These advances have greatly increased our understanding of the physiological and pathophysiological functions of P2X and P2Y receptors, but investigation of the clinical usefulness of selective ligands is at an early stage. Nonetheless, the evidence considered in this review demonstrates clearly that various cardiovascular disorders, including vasospasm, hypertension, congestive heart failure and cardiac damage during ischemic episodes, may be viable targets. With further development of novel, selective agonists and antagonists, our understanding will continue to improve and further therapeutic applications are likely to be discovered.

Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Humans; Purinergic P2X Receptor Agonists; Purinergic P2X Receptor Antagonists; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2X; Receptors, Purinergic P2Y